This reduced response is often referred to as tachyphylaxis, where the body gradually adapts to the external hormone and makes it less effective with continued use
(Kaunas) 59, 2184 (2023)
Formulated with 0.9% benzyl alcohol as a preservative , it is designed to inhibit microbial growth, allowing for multi-use applications within controlled research settings
Common side effects (usually mild) Injection-related: Injection site redness or irritation Mild pain at injection site Temporary skin induration GH-related: Water retention (usually temporary) Mild headaches (especially initially) Increased hunger (less than GHRP-6) Tingling or numbness (rare, usually at high doses) Sleep-related: Vivid dreams (often reported, not necessarily unpleasant) Temporary sleep disturbance during adjustment Less common side effects At higher doses or prolonged use: Joint stiffness or mild carpal tunnel symptoms Flushing Dizziness Fatigue (paradoxically, sometimes) What Ipamorelin typically doesn't cause Unlike other GHRPs: No significant cortisol elevation No significant prolactin increase No intense hunger spikes No blood sugar disruption Managing side effects For water retention: Usually resolves within 2-4 weeks Reduce sodium intake Stay well-hydrated Consider reducing dose temporarily For headaches: Often occur during first week Ensure proper hydration Start with lower dose and titrate up Usually resolve with continued use For injection site reactions: Rotate injection sites Ensure proper injection technique Allow alcohol to dry before injecting Use fresh needles Contraindications Do not use Ipamorelin if you have: Active cancer or history of cancer Uncontrolled diabetes Severe cardiovascular disease Pregnancy or breastfeeding Known allergy to peptide components Use with caution if you have: Diabetes (monitor blood sugar closely) History of carpal tunnel syndrome Pituitary disorders Any condition affected by growth hormone For comprehensive safety information, see our peptide safety guide
CJC-1295 acts as a GHRH analog, amplifying the size of those GH pulses
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism
